Company intelligence / Profile preview

Tyra Biosciences

Carlsbad, California, United Statestyra.bio ↗

Ownership: Public · TYRA
Employees: ~59
Development stage: Phase 2

Overview

TYRA-300 has shown high anti-tumor activity with favorable tolerability in heavily pre-treated cancer patients in the SURF301 study. The company has received FDA clearance for three INDs and is advancing TYRA-300 into three Phase 2 studies for different indications.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

dabogratinib

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.6B
Total revenue: $0
Enterprise value: $1.2B

Beyond the preview

Go deeper on Tyra Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyra Biosciences.

Explore the full profile